Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) is a biotechnology company focused on the development of a diagnostic for Alzheimer's disease and thereputics for Parkinson's disease, severe burns and ophthalmological disorders. The Company’s lead product candidates are LymPro® and Eltoprazine. LymPro is a stage independent diagnostic for Alzheimer’s disease, based on the fundamental biology of cell cycle dysregulation that serves as a biologic event correlating to the amyloid and tau hypothesis. Amarantus is preparing to initiate Phase 2b studies of Eltoprazine, a 5HT1a/1b partial agonist small molecule for the treatment of Parkinson’s disease levodopa-induced-dyskinesia (PD-LID), and adult attention deficit hyperactivity disorder (Adult ADHD).

Corporate Highlights:• Derisked business model yields four pillars of expected transformational growth - Robust pipeline with multiple clinical stage products and diagnostic candidates - First in class product candidates address multiple billion dollar markets

• Proven Management, Board of Directors and Advisors - Core competence in identifying and developing undervalued assets

• Proprietary protein discovery platform, PhenoGuard™

- Allows rapid discovery of novel secreted human proteins with biological activity for specific indications • First application of PhenoGuard was in the discovery of MANF - MANF, a naturally occuring protein with the purpose of reducing and preventing apotosis - Orphan ophthalmology franchise with the potential of addressing mutiple indications with a market opportunity of $10B-plus

• Pending acquisition of Engineered Skin Substitute (ESS-W) for the treatment of severe burns (Stage 3 and Stage 4) - Phase 2 Clinical Study in 2Q 2015 - Granted Orphan Drug Designation

LeadershipGerald E. Commissiong President, Chief Executive Officer

Robert Farrell, J.D. Chief Financial Officer

David A Lowe, Ph.D Leading Portfolio Management

Charlotte Keywood, M.D. Chief Medical Officer, Therapeutics Division John W. Commissiong, Ph.D. Chief Scientific Officer

Elise Brownell, Ph.D. Senior Vice President, Operations and Project Management

OTCQB: AMBS

Share Price: $0.08

Market Cap: $68M

Shares: 799M

As of December 5, 2014

AmarantusBioScience

Amarantus

DiagnosticsLymPro/NuroPro

TherapeuticsEltoprazine/

MANF

Regen MedESS-W

DiscoveryPhenoGuard

Amarantus Holding Structure Yields Four Pillars of Expected Transformational Growth

Diagnostic Candidate Pre-Clinical Phase 1 Phase 2 Phase 3 Opportunity

LymPro Test: Alzheimer’s (CLIA)

Therapeutic Candidate Pre-Clinical Phase 1 Phase 2 Phase 3 Opportunity

Eltoprazine: Parkinson’s / Adult ADHD ESS-W: Intractable Severe Burns MANF: Retinitis Pigmentosa

Board of Directors

Gerald E. Commissiong President & Chief Executive Officer

John W. Commissiong, Ph.D. Chief Scientific Officer

Robert L. Harris Independent Director, Compliance Officer, Nominating and Governing Chair

Donald D. Huffman Independent Director, Audit Committee Chair

David A. Lowe, Ph.D .Director Iain Ross Independent Director Joseph Rubinfeld, Ph.D.Independent Director

Amarantus BioScience Holdings, Inc.

655 Montgomery StreetSuite 900

San Francisco, CA 94111info@amarantus.com

Phone: (415) 688-4484Fax: (408) 852-4427

Potential spinoffin 2015

Potential partnershipin 2016

Potential spinoff /partner in 2017Potential PoC in

orphan ocular in 2018

LymPro: Expected to Rapidly Establish a Market Leading Position • Stage-independent diagnostic blood test for Alzheimer’s disease • Initially targeted for investigational use in pharma clinical trials • Clinical Laboratory Improvement Amendments (CLIA) certification targeted for 2015Eltoprazine: First-in-Class Product Addressing Key Unmet Need of Parkinson’s • 5HT1a /1b partial agonist small molecule in Phase 2 for the treatment of Parkinson’s LID and adult ADHD • Encouraging safety profile with ~700 patients exposed • Addressing $8.3B adult ADHD and $3B Parkinson’s drug markets • Originally developed by Solvay (now Abbvie) ESS-W: Game-Changing Treatment Solution for Severe Burns • Tissue-engineered skin substitute prepared from autologous skin cells for treatment of stage 3 and stage 4 full-thickness severe burns • Applicable for both epidermal and dermal layers • Phase 2 clinical trial initiating in Q2/2015 • Orphan Drug Designation granted • Acquired from LonzaMANF: Crown Jewel with Potential to Yield Multiple Blockbuster Opportunities • Highly potent, neurotrophic factor for the treatment of several apoptosis-related disorders • Disease-modifying treatment for Retinitis Pigmentosa (RP) and the opportunity to address Parkinson’s, Diabetes, Heart Disease and Glaucoma • $1B-plus opportunity in RP with total market potential of $10B

Pipeline: From Discovery to Commercialization

Investigational-use enabling anaylitical validation Confirmatory clinical performance data Spinoff

IND submission Initiate Phase 2b clinical trial

Initiate Phase 2 clinical trial

FDA Orphan Drug Designation (ODD) application response File ODD for RP in Europe + 2nd w/FDA GMP manufacturing to support human clinical trials

Q4/14Q1/15 Q2/15

MANF

LymPro

ESS-W

Near-term Milestones Expected to Build Significant Momentum

Eltoprazine

AmarantusBioScience